Equities Analysts Offer Predictions for SPRY Q2 Earnings

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – Investment analysts at Leerink Partnrs reduced their Q2 2025 earnings per share (EPS) estimates for shares of ARS Pharmaceuticals in a report released on Wednesday, May 14th. Leerink Partnrs analyst R. Ruiz now forecasts that the company will earn ($0.43) per share for the quarter, down from their previous forecast of ($0.37). The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.55) per share. Leerink Partnrs also issued estimates for ARS Pharmaceuticals’ Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($1.50) EPS, FY2026 earnings at ($0.71) EPS, FY2027 earnings at $0.35 EPS and FY2028 earnings at $2.25 EPS.

ARS Pharmaceuticals (NASDAQ:SPRY) last released its earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.35). The company had revenue of $7.97 million during the quarter, compared to analyst estimates of $7.48 million.

A number of other research analysts have also issued reports on the stock. Scotiabank assumed coverage on shares of ARS Pharmaceuticals in a research note on Friday, March 7th. They set a “sector outperform” rating and a $30.00 price target on the stock. Oppenheimer started coverage on ARS Pharmaceuticals in a research note on Monday, February 10th. They set an “outperform” rating and a $40.00 target price for the company. Finally, William Blair reaffirmed an “outperform” rating on shares of ARS Pharmaceuticals in a report on Monday, March 3rd. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $31.00.

ARS Pharmaceuticals Price Performance

NASDAQ:SPRY opened at $14.33 on Monday. The firm has a market cap of $1.41 billion, a price-to-earnings ratio of -28.10 and a beta of 0.84. ARS Pharmaceuticals has a 1-year low of $7.55 and a 1-year high of $18.51. The firm’s fifty day moving average price is $13.43 and its 200 day moving average price is $12.87.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in SPRY. Wellington Management Group LLP boosted its stake in shares of ARS Pharmaceuticals by 0.6% during the 4th quarter. Wellington Management Group LLP now owns 163,252 shares of the company’s stock worth $1,722,000 after purchasing an additional 917 shares during the last quarter. Rhumbline Advisers boosted its position in ARS Pharmaceuticals by 2.9% during the fourth quarter. Rhumbline Advisers now owns 65,163 shares of the company’s stock worth $687,000 after acquiring an additional 1,824 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in ARS Pharmaceuticals by 10.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 20,607 shares of the company’s stock worth $217,000 after acquiring an additional 1,962 shares during the last quarter. Mariner LLC grew its stake in ARS Pharmaceuticals by 5.8% in the 4th quarter. Mariner LLC now owns 35,908 shares of the company’s stock worth $379,000 after acquiring an additional 1,972 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in ARS Pharmaceuticals by 1.5% in the 1st quarter. Bank of New York Mellon Corp now owns 132,213 shares of the company’s stock valued at $1,663,000 after acquiring an additional 1,975 shares during the last quarter. Institutional investors and hedge funds own 68.16% of the company’s stock.

Insider Transactions at ARS Pharmaceuticals

In related news, insider Eric Karas sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $14.00, for a total value of $140,000.00. Following the sale, the insider now owns 7,696 shares of the company’s stock, valued at approximately $107,744. This represents a 56.51% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Laura Shawver sold 49,600 shares of the firm’s stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $11.21, for a total value of $556,016.00. Following the transaction, the director now directly owns 210,346 shares of the company’s stock, valued at $2,357,978.66. The trade was a 19.08% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 109,602 shares of company stock valued at $1,311,041 in the last quarter. 33.50% of the stock is currently owned by corporate insiders.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.